<DOC>
	<DOCNO>NCT01126138</DOCNO>
	<brief_summary>It phase III trial explore efficacy safety vinorelbine plus capecitabine ( NX ) docetaxel plus capecitabine ( TX ) first line treatment follow capecitabine alone till Progressive Disease ( PD ) . We plan enroll 200 pt limited budget non-inferior trend two curve anticipate .</brief_summary>
	<brief_title>Capecitabine ( NX ) Versus Docetaxel Plus Capecitabine ( TX ) 1-line Chemotherapy Metastatic Breast Cancer ( MBC )</brief_title>
	<detailed_description>We design randomize non-inferiority study . Main Inclusion &amp; exclusion Criteria include : 1 ) Histologically cytologically confirm breast cancer unresectable locally advanced and/or metastatic disease ; 2 ) Untreated patient unresectable locally advanced and/or metastatic disease ; 3 ) least 1 lesion measurable radiological method ( RECIST criterion ) ; 4 ) Karnofsky Performance Status ( KPS ) ≥70 ; 5 ) normal Adequate hepatic , renal , bone marrow function ; 6 ) Life expectancy least 12 week ; 7 ) No previous chemotherapy metastatic breast cancer . Primary endpoint Progression free survival ( PFS ) , second endpoint safety profile ( National Cancer Institute-Common Toxicity Criteria 3.0 , NCI-CTC 3.0 ) , overall survival response rate . During Primary study treatment , Arm A : Capecitabine : 1,000 mg/m2 per os ( PO ) twice daily ( day 1-14 ) , Vinorelbine 25 mg/m2 intravenous ( IV ) 3 hour day 1 8 , every 3 week , 21 day one cycle 6-8 cycle require ; Arm B : Capecitabine : 1,000 mg/m2 PO twice daily ( day 1-14 ) , Docetaxel 75 mg/m2 IV 3 hour day 1 , every 3 week , 21 day one cycle 6-8 cycle require . Patients respond ( complete partial ) , whose disease stable follow Capecitabine : 1,000 mg/m2 PO twice daily ( day 1-14 ) 21 day one cycle progression unacceptable toxicity</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Ductal , Breast</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Written sign inform consent prior begin specific protocol procedure . Pathologically confirm breast cancer document metastatic locally advanced disease . Measurable disease ( RECIST criterion ) least 1 lesion measurable radiological method KPS &gt; =70 Adjuvant and/or Neoadjuvant chemotherapy , include anthracycline permit Hormone therapy earlystage metastatic breast cancer permit hormonal receptor positive . Treatment Herceptin earlystage metastatic breast cancer permit HER2 positive Patients conclude prior radiation therapy least 14 day enrollment . Laboratory requirement : Hematology Absolute neutrophil count &gt; =1,500 /μl ; Platelets &gt; =100,000 /μl ; Hemoglobin &gt; =10 g/dl Liver function Total bilirubin &lt; =2 time ULN ASAT ( SGOT ) ALAT ( SGPT ) &lt; =2.5 time UNL without liver metastasis &lt; =5.0 time liver metastasis Glucose &lt; =200 mg/dL Renal function Serum creatinine &lt; =140 mol/l Life expectancy least 12 week Patients must accessible treatment followup . Patients recover acute reversible effect prior treatment . This generally mean least 3 week elapse since prior chemotherapy , adjuvant Neoadjuvant treatment . least 4 week since prior ( radical ) radiotherapy major surgery Women pregnant breast feed History brain and/or leptomeningeal metastases Previous chemotherapy metastatic breast cancer Past current history malignant neoplasm breast carcinoma , except curatively treat non melanoma skin cancer , situ carcinoma cervix cancer curatively treat evidence disease least 5 year Preexisting neuropathy grade 1 accord NCICCTC 3.0 Psychiatric disorder condition would prevent pt . compliance Other serious illness medical condition : Congestive heart failure , unstable angina pectoris , previous history myocardial infarction within 6 month prior study entry , uncontrolled hypertension determine Investigator high risk uncontrolled , arrhythmia . History significant neurological psychiatric disorder include psychotic disorder , dementia seizure would prohibit understanding give informed consent . Active uncontrolled infection . Unstable peptic ulcer , unstable diabetes mellitus contraindication use Corticosteroids . Inability take and/or absorb oral medicine Prior treatment docetaxel and/or capecitabine and/or vinorbine Concurrent treatment experimental drug , participation another clinical trial investigational drug within 30 day prior study entry</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>unresectable</keyword>
	<keyword>locally advanced</keyword>
	<keyword>metastatic</keyword>
	<keyword>breast cancer</keyword>
</DOC>